Cite
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
MLA
Atkins, Michael B., et al. “Treatment-Free Survival Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).” Journal for Immunotherapy of Cancer, vol. 12, no. 4, Apr. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2023-008293.
APA
Atkins, M. B., Jegede, O. A., Haas, N. B., Mcdermott, D. F., Bilen, M. A., Stein, M., Sosman, J., Alter, R., Plimack, E. R., Ornstein, M. C., Hurwitz, M., Peace, D. J., Einstein, D., Catalano, P. J., Hammers, H., & Regan, M. M. (2024). Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for Immunotherapy of Cancer, 12(4). https://doi.org/10.1136/jitc-2023-008293
Chicago
Atkins, Michael B, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, Mark Stein, Jeffrey Sosman, et al. 2024. “Treatment-Free Survival Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).” Journal for Immunotherapy of Cancer 12 (4). doi:10.1136/jitc-2023-008293.